Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. 1979

T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman

Parameters describing disposition and absolute oral bioavailability of quinidine were determined in ten normal male volunteers using a specific assay. Various models were compared for their ability to describe the experimental data. An intravenous quinidine gluconate and an oral quinidine sulfate solution were administered (3.74 mg/kg quinidine base). In three subjects the intravenous and oral studies were repeated. One-, two-, and three-compartment models with zero and first-order input were fitted to the plasma concentrations. The selection of the best model was made by the Akaike information criterion and by eye. After intravenous administration, plasma concentration-time curves could be adequately described by a two-compartment model. Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1). A clearance of 4.9 +/- 1.5 ml/min/kg was observed. After oral administration, three-compartment models were needed to describe the observed data in some cases. Absorption was in most cases best described by a zero-order rather than by a first-order process. The time to peak concentration varied from 23 to 121 min, the lag time was always less than 3 min, and the mean elimination rate constant was 0.00171 min -1. The mean oral bioavailability of quinidine was 0.70 +/- 0.17.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
September 1976, Clinical pharmacology and therapeutics,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
September 2009, International journal of clinical pharmacology and therapeutics,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
January 1996, Drug metabolism and disposition: the biological fate of chemicals,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
January 1993, Drug metabolism and disposition: the biological fate of chemicals,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
August 1982, British journal of clinical pharmacology,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
June 1985, International journal of clinical pharmacology, therapy, and toxicology,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
June 1985, British journal of clinical pharmacology,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
April 1999, Biopharmaceutics & drug disposition,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
January 1997, European journal of clinical pharmacology,
T W Guentert, and N H Holford, and P E Coates, and R A Upton, and S Riegelman
January 1996, European journal of clinical pharmacology,
Copied contents to your clipboard!